What is the JAK-STAT pathway?
The JAK-STAT pathway is a signalling cascade activated by cytokine-class receptors (including the growth hormone receptor) that converts extracellular ligand binding into transcriptional responses via JAK-family kinases phosphorylating STAT transcription factors. Distinguishes the cytokine-receptor signalling architecture from the receptor-tyrosine-kinase architecture used by RTKs like VEGFR2.
What the research literature says
Cytokine-class receptors — including the growth hormone receptor, prolactin receptor, and many interleukin receptors — lack intrinsic kinase activity. Signal transduction depends on constitutively-associated JAK-family kinases (Janus kinases). Ligand binding induces receptor dimerisation, which brings two JAKs into proximity, enabling trans-autophosphorylation. Activated JAKs then phosphorylate tyrosine residues on the receptor’s intracellular tail, creating docking sites for STAT (signal transducer and activator of transcription) family transcription factors.
STATs recruited to phospho-receptor docking sites are themselves phosphorylated by JAK2, dimerise, and translocate to the nucleus to drive gene-expression responses. The growth hormone receptor signals predominantly through JAK2-STAT5, with downstream gene-expression responses including hepatic IGF-1 synthesis (the canonical readout for GH-axis pharmacology research).
The Chang BPC-157 tendon-fibroblast work documented growth-hormone-receptor up-regulation as the mechanistic finding alongside the promoting effects on tendon-explant outgrowth, cell survival, and cell migration (PMID 21030672) — the JAK-STAT-driven downstream signalling is the operative pathway from the receptor up-regulation finding.
Why this matters in research context
The JAK-STAT pathway matters in peptide-research contexts as the signalling architecture for growth-hormone-receptor pharmacology. Researchers studying BPC-157’s tendon-research mechanism should account for JAK2-STAT5 downstream signalling as the operative pathway from the documented GH-receptor up-regulation finding. The pathway is distinct from the tyrosine-kinase-receptor (VEGFR2, FGFR, EGFR) signalling that dominates the angiogenic-mechanism research.
Related compounds
- BPC-157 10mg — GH-receptor up-regulation in tendon fibroblasts (JAK-STAT downstream)
Related research questions
References
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol 2011;110(3):774-780. [PMID 21030672]
- Cerovecki T et al. Gastric pentadecapeptide body protection compound BPC 157 and musculoskeletal soft tissue healing. Cell Tissue Res 2019. [PMID 30915550]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.